MX2016005760A - Inhibidores de glucogeno sintasa cinasa 3 (gsk-3). - Google Patents

Inhibidores de glucogeno sintasa cinasa 3 (gsk-3).

Info

Publication number
MX2016005760A
MX2016005760A MX2016005760A MX2016005760A MX2016005760A MX 2016005760 A MX2016005760 A MX 2016005760A MX 2016005760 A MX2016005760 A MX 2016005760A MX 2016005760 A MX2016005760 A MX 2016005760A MX 2016005760 A MX2016005760 A MX 2016005760A
Authority
MX
Mexico
Prior art keywords
gsk
inhibitors
compounds
salts
compositions
Prior art date
Application number
MX2016005760A
Other languages
English (en)
Inventor
Vivekananda M Vrudhula
Senliang Pan
John E Macor
Guanglin Luo
Ling Chen
Gene M Dubowchik
Prasanna Sivaprakasam
Swanee E Jacutin-Porte
Original Assignee
Squibb Bristol Myers Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Squibb Bristol Myers Co filed Critical Squibb Bristol Myers Co
Publication of MX2016005760A publication Critical patent/MX2016005760A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Abstract

La descripción se refiere en general a los compuestos de la fórmula I, incluyendo sus sales, así como las composiciones y métodos de uso de los compuestos para tratar trastornos asociados con GSK-3.
MX2016005760A 2013-11-06 2014-11-03 Inhibidores de glucogeno sintasa cinasa 3 (gsk-3). MX2016005760A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361900465P 2013-11-06 2013-11-06
PCT/US2014/063691 WO2015069594A1 (en) 2013-11-06 2014-11-03 Gsk-3 inhibitors

Publications (1)

Publication Number Publication Date
MX2016005760A true MX2016005760A (es) 2016-07-18

Family

ID=51982762

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016005760A MX2016005760A (es) 2013-11-06 2014-11-03 Inhibidores de glucogeno sintasa cinasa 3 (gsk-3).

Country Status (12)

Country Link
US (1) US9718804B2 (es)
EP (1) EP3066093B9 (es)
JP (1) JP2016535755A (es)
KR (1) KR102339227B1 (es)
CN (1) CN105849098A (es)
AU (1) AU2014347027A1 (es)
CA (1) CA2929528A1 (es)
EA (1) EA201690844A1 (es)
IL (1) IL245442A0 (es)
MX (1) MX2016005760A (es)
SG (1) SG11201603209XA (es)
WO (1) WO2015069594A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3066092B1 (en) 2013-11-06 2018-09-05 Bristol-Myers Squibb Company Substituted pyridine derivatives useful as gsk-3 inhibitors
WO2018081294A1 (en) 2016-10-26 2018-05-03 Rigel Pharmaceuticals, Inc. Pyrazole amide compounds as irak inhibitors
US10774086B2 (en) * 2016-11-28 2020-09-15 Bristol-Myers Squibb Company GSK-3 inhibitors
ES2878078T3 (es) * 2016-11-28 2021-11-18 Bristol Myers Squibb Co Inhibidores de GSK-3
JP6977037B2 (ja) * 2016-11-28 2021-12-08 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company Ｇｓｋ−３阻害剤
BR112019013593A2 (pt) 2016-12-28 2020-01-07 Minoryx Therapeutics S.L. Compostos de isoquinolina, métodos para sua preparação, e usos terapêuticos dos mesmos em afecções associadas à alteração da atividade de beta galactosidase
EP3601250A4 (en) * 2017-03-27 2020-11-25 Pharmakea, Inc. APOPTOSIS SIGNAL REGULATION KINASE 1 (ASK 1) INHIBITOR COMPOUNDS
JP2020533317A (ja) 2017-09-07 2020-11-19 オーガスタ ユニバーシティ リサーチ インスティテュート，インコーポレーテッド 特異的ａｋｔ３活性化剤およびその使用
CA3117222A1 (en) 2018-11-19 2020-05-28 Amgen Inc. Kras g12c inhibitors and methods of using the same
MA54546A (fr) * 2018-12-20 2022-03-30 Amgen Inc Amides d'hétéroaryle utiles en tant qu'inhibiteurs de kif18a
EP3920885A1 (en) 2019-02-08 2021-12-15 Frequency Therapeutics, Inc. Valproic acid compounds and wnt agonists for treating ear disorders
CN114401953A (zh) * 2019-08-02 2022-04-26 美国安进公司 Kif18a抑制剂
AU2020324963A1 (en) * 2019-08-02 2022-02-24 Amgen Inc. KIF18A inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6756385B2 (en) 2000-07-31 2004-06-29 Pfizer Inc. Imidazole derivatives
WO2005028484A1 (en) 2003-09-19 2005-03-31 F. Hoffmann-La Roche Ag Thiazolopyridine derivatives as adenosine receptor ligands
EP1751133B1 (en) * 2004-04-28 2010-04-14 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of rock and other protein kinases
SE0401345D0 (sv) 2004-05-25 2004-05-25 Astrazeneca Ab Therapeutic compounds: Pyridine as scaffold
US20080146536A1 (en) 2005-08-16 2008-06-19 Pharmacopeia, Inc. 2-Aminoimidazopyridines for treating neurodegenerative diseases
CN101801963A (zh) 2007-07-09 2010-08-11 阿斯利康(瑞典)有限公司 用于治疗增殖性疾病的三取代的嘧啶衍生物
KR20100117137A (ko) * 2008-02-27 2010-11-02 메르크 파텐트 게엠베하 당뇨병 치료를 위한 카르복사마이드-헤테로아릴유도체
CN102336720B (zh) 2011-03-02 2016-01-13 华中科技大学 2-氨基噻唑衍生物及制备方法和应用
EP2712862A1 (en) * 2012-09-28 2014-04-02 Splicos New anti-invasive compounds
EP3066092B1 (en) 2013-11-06 2018-09-05 Bristol-Myers Squibb Company Substituted pyridine derivatives useful as gsk-3 inhibitors

Also Published As

Publication number Publication date
KR20160078494A (ko) 2016-07-04
US20160272621A1 (en) 2016-09-22
EP3066093B9 (en) 2018-02-07
AU2014347027A1 (en) 2016-06-23
SG11201603209XA (en) 2016-05-30
CA2929528A1 (en) 2015-05-14
US9718804B2 (en) 2017-08-01
EP3066093A1 (en) 2016-09-14
EP3066093B1 (en) 2017-10-04
EA201690844A1 (ru) 2016-08-31
CN105849098A (zh) 2016-08-10
KR102339227B1 (ko) 2021-12-13
IL245442A0 (en) 2016-06-30
WO2015069594A1 (en) 2015-05-14
JP2016535755A (ja) 2016-11-17

Similar Documents

Publication Publication Date Title
PH12019501321A1 (en) Methods of treating or preventing cholesterol related disorders
MX2016005760A (es) Inhibidores de glucogeno sintasa cinasa 3 (gsk-3).
AU2015207757A8 (en) N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of SHP2
MX2018000396A (es) Compuestos aza sustituidos como inhibidores de cinasa 4 asociada al receptor de interleucina 1 (irak-4).
PH12016500676A1 (en) Pyrimidine fgfr4 inhibitors
PH12016500105A1 (en) Sulfonamides as modulators of sodium channels
PH12016500511A1 (en) Selective grp94 inhibitors and uses thereof
MX2016004927A (es) Composiciones utiles para tratar trastornos relacionados con kit.
MX2016017147A (es) Compuestos de indazole substituidos como inhibidores de irak4.
MX2017008444A (es) Picolinamidas como fungicidas.
MX364486B (es) Derivados de piridazinona-amidas.
MA40076A (fr) Inhibiteurs de syk
MX2016002794A (es) Compuestos antiproliferativos.
MX2020001756A (es) Compuestos deuterados del inhibidor vmat y el uso de dichos compuestos.
MD20150071A2 (ro) Compuşi azabenzimidazolici ca inhibitori ai PDE4 izoenzimelor pentru tratamentul tulburărilor SNC şi altor afecţiuni
UA118666C2 (uk) Похідні піразолу
PH12015502611A1 (en) Heterocyclic compounds as hedgehog signaling pathway inhibitors
MX2016003823A (es) Inhibidor selectivo de fosfatidil-inositol 3-cinasa-gamma.
MX2016005759A (es) Derivados de piridina sustituidos, utiles como inhibidores de glucogeno sintasa cinasa 3 (gsk-3).
PH12016500347A1 (en) Triazolopyridine compounds, compositions and methods of use thereof
MX2016006975A (es) Compuestos, composicion farmaceutica y metodos para su uso en el tratamiento de enfermedades inflamatorias.
PH12015502032A1 (en) Azetidinyloxyphenylpyrrolidine compounds
TW201613884A (en) Selective NR2B antagonists
EA201391586A1 (ru) ИНГИБИТОРЫ 17α-ГИДРОКСИЛАЗЫ/C-ЛИАЗЫ
EA201591449A1 (ru) Способы получения противораковых композиций